Ipamorelin vs Sermorelin

Ipamorelin: Selective growth hormone secretagogue with minimal side effects. Typical dose 100-300 mcg. Sermorelin: The original GHRH analog and the first FDA-approved peptide secretagogue. Typical dose 200-500 mcg. Both fall under the Growth Hormone category.

Stacking Ipamorelin with Sermorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Ipamorelin is typically dosed: Two to three times daily (SubQ) for GH optimization and anti-aging; Two to three times daily for Combined with CJC-1295 (Mod GRF). Sermorelin is typically dosed: Once daily before bed (SubQ) for GH optimization / anti-aging; Once daily before bed for Combined with Ipamorelin; Once daily before bed for Pediatric GHD (historical, prescribing-physician only).

Ipamorelin: Not FDA approved for human use. Clinical development discontinued by Novo Nordisk. Sermorelin: Previously FDA approved (1997, as Geref) for pediatric GHD. Brand discontinued 2008. Available in the US via compounding pharmacies on prescription.